Immunosuppressive activities of adenosine in cancer

被引：216
作者：
Allard, Bertrand [1 ,2 ]
Beavis, Paul A. [3 ,4 ]
Darcy, Phillip K. [3 ,5 ]
Stagg, John [1 ,2 ]
机构：
[1] CRCHUM, Inst Canc Montreal, 900 Rue St Denis, Montreal, PQ H2X0A9, Canada
[2] Univ Montreal, Fac Pharm, Pavillon Jean Coutu,2940 Chemin Polytech, Montreal, PQ, Canada
[3] Peter MacCallum Canc Ctr, Canc Immunol Program, East Melbourne, Vic, Australia
[4] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3010, Australia
[5] Univ Melbourne, Dept Pathol, Parkville, Vic, Australia
来源：
CURRENT OPINION IN PHARMACOLOGY | 2016年 / 29卷
基金：
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词：
REGULATORY T-CELLS; NEGATIVE BREAST-CANCER; MOUSE MELANOMA MODEL; NATURAL-KILLER-CELLS; EXTRACELLULAR ADENOSINE; A(2A) RECEPTOR; TUMOR-GROWTH; ECTONUCLEOTIDASE EXPRESSION; HIF-1-DEPENDENT REPRESSION; CD11B(+)GR1(+) CELLS;
D O I：
10.1016/j.coph.2016.04.001
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Multiple immunosuppressive mechanisms impede anti-tumor immunity. Among them, the accumulation of extracellular adenosine is a potent and widespread strategy exploited by tumors to escape immunosurveillance through the activation of purinergic receptors. In the immune system, engagement of A2a and A2b adenosine receptors is a critical regulatory mechanism that protects tissues against excessive immune reactions. In tumors, this pathway is hijacked and hinders antitumor immunity, promoting cancer progression. Different groups have highlighted the therapeutic potential of blocking CD73-dependent adenosine-mediated immunosuppression to reinstate anti-tumor immunity. Phase clinical trials evaluating anti-CD73 antibodies and A2a receptor antagonists in cancer patients are currently ongoing. We here review the recent literature on the immunosuppressive effects of extracellular adenosine and discuss the development of adenosine inhibitors.
引用
收藏
页码：7 / 16
页数：10
相关论文
共 107 条
  • [91] Tissue-Nonspecific Alkaline Phosphatase Acts Redundantly with PAP and NT5E to Generate Adenosine in the Dorsal Spinal Cord
    Street, Sarah E.
    Kramer, Nicholas J.
    Walsh, Paul L.
    Taylor-Blake, Bonnie
    Yadav, Manisha C.
    King, Ian F.
    Vihko, Pirkko
    Wightman, R. Mark
    Millan, Jose Luis
    Zylka, Mark J.
    [J]. JOURNAL OF NEUROSCIENCE, 2013, 33 (27) : 11314 - U1104
  • [92] Knockdown of Oncogenic KRAS in Non-Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
    Sunaga, Noriaki
    Shames, David S.
    Girard, Luc
    Peyton, Michael
    Larsen, Jill E.
    Imai, Hisao
    Soh, Junichi
    Sato, Mitsuo
    Yanagitani, Noriko
    Kaira, Kyoichi
    Xie, Yang
    Gazdar, Adi F.
    Mori, Masatomo
    Minna, John D.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2011, 10 (02) : 336 - 346
  • [93] Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia
    Synnestvedt, K
    Furuta, GT
    Comerford, KM
    Louis, N
    Karhausen, J
    Eltzschig, HK
    Hansen, KR
    Thompson, LF
    Colgan, SP
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (07) : 993 - 1002
  • [94] Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells
    Terp, Mikkel G.
    Olesen, Kristina A.
    Arnspang, Eva C.
    Lund, Rikke R.
    Lagerholm, B. Christoffer
    Ditzel, Henrik J.
    Leth-Larsen, Rikke
    [J]. JOURNAL OF IMMUNOLOGY, 2013, 191 (08) : 4165 - 4173
  • [95] Human ectonucleotidase-expressing CD25high Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions
    Thibaudin, Marion
    Chaix, Marie
    Boidot, Romain
    Vegran, Frederique
    Derangere, Valentin
    Limagne, Emeric
    Berger, Helene
    Ladoire, Sylvain
    Apetoh, Lionel
    Ghiringhelli, Francois
    [J]. ONCOIMMUNOLOGY, 2016, 5 (01):
  • [96] Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
    Topalian, Suzanne L.
    Drake, Charles G.
    Pardoll, Drew M.
    [J]. CANCER CELL, 2015, 27 (04) : 450 - 461
  • [97] CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer
    Turcotte, Martin
    Spring, Kathleen
    Pommey, Sandra
    Chouinard, Guillaume
    Cousineau, Isabelle
    George, Joshy
    Chen, Gregory M.
    Gendoo, Deena M. A.
    Haibe-Kains, Benjamin
    Karn, Thomas
    Rahimi, Kurosh
    Le Page, Cecile
    Provencher, Diane
    Mes-Masson, Anne-Marie
    Stagg, John
    [J]. CANCER RESEARCH, 2015, 75 (21) : 4494 - 4503
  • [98] Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies
    Verbrugge, Inge
    Hagekyriakou, Jim
    Sharp, Leslie L.
    Galli, Mara
    West, Alison
    McLaughlin, Nicole M.
    Duret, Helene
    Yagita, Hideo
    Johnstone, Ricky W.
    Smyth, Mark J.
    Haynes, Nicole M.
    [J]. CANCER RESEARCH, 2012, 72 (13) : 3163 - 3174
  • [99] Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor
    Waickman, Adam T.
    Alme, Angela
    Senaldi, Liana
    Zarek, Paul E.
    Horton, Maureen
    Powell, Jonathan D.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (06) : 917 - 926
  • [100] NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity
    Wang, H.
    Lee, S.
    Lo Nigro, C.
    Lattanzio, L.
    Merlano, M.
    Monteverde, M.
    Matin, R.
    Purdie, K.
    Mladkova, N.
    Bergamaschi, D.
    Harwood, C.
    Syed, N.
    Szlosarek, P.
    Briasoulis, E.
    McHugh, A.
    Thompson, A.
    Evans, A.
    Leigh, I.
    Fleming, C.
    Inman, G. J.
    Hatzimichael, E.
    Proby, C.
    Crook, T.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 106 (08) : 1446 - 1452
234567891011